138 related articles for article (PubMed ID: 36740368)
1. CD4/CD8 double-negative T-cell lymphoma successfully treated with a combination of bexarotene and total skin electron beam therapy.
Tanigawa A; Fukumoto T; Imamura S; Nakamura K; Tanaka T; Itoh T; Nakano E; Nishigori C; Kubo A
J Dermatol; 2023 Jul; 50(7):e210-e212. PubMed ID: 36740368
[No Abstract] [Full Text] [Related]
2. Bexarotene--an alternative therapy for progressive cutaneous T-cell lymphoma? First experiences.
Bohmeyer J; Stadler R; Kremer A; Nashan D; Muche M; Gellrich S; Luger T; Sterry W
J Dtsch Dermatol Ges; 2003 Oct; 1(10):785-9. PubMed ID: 16281814
[TBL] [Abstract][Full Text] [Related]
3. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
[TBL] [Abstract][Full Text] [Related]
4. Low-dose total skin electron beam therapy plus oral bexarotene maintenance therapy for cutaneous T-cell lymphoma.
Elsayad K; Rolf D; Sunderkötter C; Weishaupt C; Müller EC; Nawar T; Stranzenbach R; Livingstone E; Stadler R; Steinbrink K; Moritz RKC; Eich HT
J Dtsch Dermatol Ges; 2022 Mar; 20(3):279-285. PubMed ID: 34984837
[TBL] [Abstract][Full Text] [Related]
5. CD4/CD8 double-negative T-cell lymphoma: a variant of primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma?
Miyauchi T; Abe R; Morita Y; Adachi M; Shiba K; Hamade Y; Saito N; Nishimura M; Ibata M; Okada K; Shigematsu A; Endo T; Kawai K; Teshima T; Shimizu H
Acta Derm Venereol; 2015 Nov; 95(8):1024-5. PubMed ID: 25792011
[No Abstract] [Full Text] [Related]
6. Late-onset bexarotene-induced CD4 lymphopenia in a cutaneous T-cell lymphoma patient.
Eshagh K; Romero LS; So JK; Zhao XF
Cutis; 2017 Feb; 99(2):E30-E34. PubMed ID: 28319634
[TBL] [Abstract][Full Text] [Related]
7. Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms.
Duvic M
Clin Lymphoma; 2000 Nov; 1 Suppl 1():S51-5. PubMed ID: 11707865
[TBL] [Abstract][Full Text] [Related]
8. Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. The influence of additional therapy after total skin electron beam radiation.
Licata AG; Wilson LD; Braverman IM; Feldman AM; Kacinski BM
Arch Dermatol; 1995 Apr; 131(4):432-5. PubMed ID: 7726585
[TBL] [Abstract][Full Text] [Related]
9. Total skin electron beam therapy may be associated with improvement of peripheral blood disease in Sézary syndrome.
Introcaso CE; Micaily B; Richardson SK; Junkins-Hopkins JM; Yoon JS; Kim EJ; Vittorio CC; Rook AH
J Am Acad Dermatol; 2008 Apr; 58(4):592-5. PubMed ID: 18249469
[TBL] [Abstract][Full Text] [Related]
10. Evolution of clinical and molecular responses to bexarotene treatment in cutaneous T-cell lymphoma.
Ballanger F; Nguyen JM; Khammari A; Dréno B
Dermatology; 2010; 220(4):370-5. PubMed ID: 20484880
[TBL] [Abstract][Full Text] [Related]
11. Fatal Case of Primary Cutaneous Aggressive T-Cell Lymphoma Switching From a CD4+ to a CD8+ Phenotype: Progressive Disease With Bexarotene and Romidepsin Treatment.
Johnson WT; Leeman-Neill RJ; Patel P; Ho J; Grandinetti LM; Jedrych J; Craig FE
Am J Dermatopathol; 2016 Nov; 38(11):832-837. PubMed ID: 27322928
[TBL] [Abstract][Full Text] [Related]
12. Extracutaneous tumour mass following bexarotene and interferon therapy of primary cutaneous CD30+ large cell lymphoma.
Kreuter A; Altmeyer P; Gambichler T
Acta Derm Venereol; 2006; 86(3):274-5. PubMed ID: 16710601
[No Abstract] [Full Text] [Related]
13. Optimizing bexarotene therapy for cutaneous T-cell lymphoma.
Whitmore SE
J Am Acad Dermatol; 2004 Sep; 51(3):482; author reply 482-3. PubMed ID: 15338005
[No Abstract] [Full Text] [Related]
14. Efficacy and safety of bexarotene combined with photo(chemo)therapy for cutaneous T-cell lymphoma.
Morita A; Tateishi C; Muramatsu S; Kubo R; Yonezawa E; Kato H; Nishida E; Tsuruta D
J Dermatol; 2020 May; 47(5):443-451. PubMed ID: 32189402
[TBL] [Abstract][Full Text] [Related]
15. Primary cutaneous aggressive epidermotropic CD8+ T cell lymphoma with a chronic and indolent course. Is this different from peripheral T cell lymphoma?
Gomez Vazquez M; Navarra Amayuelas R
Dermatol Online J; 2012 Mar; 18(3):11. PubMed ID: 22483522
[TBL] [Abstract][Full Text] [Related]
16. Low-Dose Total Skin Electron Beam Therapy as Part of a Multimodality Regimen for Treatment of Sézary Syndrome: Clinical, Immunologic, and Molecular Analysis.
Durgin JS; Jariwala NN; Wysocka M; Zhang KK; Maity A; Benoit B; Plastaras JP; Lewis DJ; Rosenthal JM; Teague JE; Berg S; Del Guzzo C; Kim EJ; Vittorio C; Haun PL; Samimi SS; Villasenor-Park J; Inverso J; Clark RA; Rook AH
JAMA Dermatol; 2021 Jan; 157(1):90-95. PubMed ID: 33112366
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of cutaneous T-cell lymphoma with retinoid receptor X-selective ligands: endocrine and metabolic disorders].
Avilés Pérez MD; Luna López V; Rodríguez Nevado I; de Argila Fernández-Durán D; Díaz Pérez de Madrid J
An Med Interna; 2007 Dec; 24(12):595-8. PubMed ID: 18278999
[TBL] [Abstract][Full Text] [Related]
18. [Cutaneous large cell anaplastic Ki-1 (CD 30) positive T-cell lymphoma].
Duve S; Cerroni L; Rakoski J; Soyer HP
Hautarzt; 1996 Apr; 47(4):294-8. PubMed ID: 8655315
[TBL] [Abstract][Full Text] [Related]
19. Topical and oral bexarotene.
Schadt CR
Dermatol Ther; 2013; 26(5):400-3. PubMed ID: 24099070
[TBL] [Abstract][Full Text] [Related]
20. Treatment of cutaneous T cell lymphoma.
Stadler R
Skin Pharmacol Appl Skin Physiol; 2002; 15(3):139-46. PubMed ID: 12077466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
